Risk of Serious Infections With Vedolizumab Versus Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease
Julien Kirchgesner, Rishi Desai, Laurent Beaugerie, Sebastian Schneeweiß, Seoyoung C. Kim
Topics & Concepts
VedolizumabMedicineInflammatory bowel diseaseInternal medicineTumor necrosis factor alphaGastroenterologyUlcerative colitisUstekinumabCrohn's diseaseTumor necrosis factorsDiseaseInfliximabInflammatory Bowel DiseaseRheumatoid Arthritis Research and TherapiesBiosimilars and Bioanalytical Methods